-+ 0.00%
-+ 0.00%
-+ 0.00%

A U.S. Federal Appeals Court Has Partially Overturned A Lower Court's Injunction, Allowing Avadel Pharmaceuticals To Seek FDA Approval And Market Its Narcolepsy Drug, Lumryz, For Idiopathic Hypersomnia, While Upholding The Ban On Clinical Trials And Open-Label Extensions

Benzinga·05/06/2025 14:47:20
Listen to the news

- Court Filing
Case: 24-2277